Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 1, 1998, Pages 71-80

  Eisele, Bernd ^a   Lamy, Maurice ^b  

^a Centeon Pharma GmbH   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antithrombin (AT III); Clinical trials; DIC; Multiple organ failure; Severe sepsis

Indexed keywords

ANTIINFECTIVE AGENT; ANTITHROMBIN III CONCENTRATE; CYTOKINE; ENDOTOXIN; TUMOR NECROSIS FACTOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CRITICAL ILLNESS; DISEASE SEVERITY; ENDOTHELIUM CELL; EXPERIENCE; HUMAN; INCIDENCE; MEDIATOR RELEASE; MULTIPLE ORGAN FAILURE; PREVALENCE; PRIORITY JOURNAL; SEPSIS;

EID: 0031881384     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995825     Document Type: Article

References (50)

1. Parillo JE. Septic shock in humans: clinical evaluation, pathophysiology and therapeutic approach. In: Shoemaker WC, Thompson WL, Holbrook P, eds. Textbook of Critical Care. 2nd ed. Philadelphia, PA: WB Saunders; 1989;1006-1023
2. Parillo JE, Parker MM, Natanson C. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990;113:227-242
3. Bone RC. Sepsis and coagulation. An important link. Chest 1992;101:594-596
4. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 1115:457-469
5. Pinner RV. Trends in infectious disease mortality. JAMA 1996;275:189-193
6. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: A valid clinical entity. Crit Care Med 1989;17:389-393
7. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-1843
8. Bone RC, Balk RA, Cerra FB. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
9. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991;163:1177-1184
10. Bone RC. A critical evaluation of new agents for the treatment of sepsis. JAMA 1991;266:1686-1691
11. van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520-2526
12. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-1835
13. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266: 1097-1102
14. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324: 429-436
15. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994;121:1-5
16. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995;273:934-941
17. Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 1990;136:103-110
18. Remick DG, Kunkel RG, Larric JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987;56:583-590
19. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165-172
20. van der Poll T, Büller HR, ten Cate H. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1627
21. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 1992;101:816-823
22. Dickneite G, Pâques EP. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis. Thromb Haemostas 1993;69:98-102
23. Hinshaw LB. Sepsis/septic shock: Participation of the microcirculation. Crit Care Med 1996;24:1072-1078
24. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemostas 1997;77:408-423
25. Bick RL. Disseminated intravascular coagulation. Med Clin North Am 1994;78:511-543
26. Bick RL. Disseminated intravascular coagulation: Objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thromb/Hemostas 1995;1:3-23
27. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32(Suppl 2):19-33
28. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
29. Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR. Granulocyte protease and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J Lab Clin Med 1994;123:874-881
30. Yamauchi T, Umeda F, Inogochi T. Antithrombin III stimulated prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;29:1404-1411
31. Okajima K, Uchiba M, Murakami K. Antithromhin replacement in DIC and MOF. In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer Verlag; 1995; 457-464
32. Abildgaard CF, Corrigan JJ, Seeler RA. Meningococcemia associated with intravascular coagulation. Pediatrics 1967;40:78-87
33. Rubenberg WL, Baker LR, McBride JA. Intravascular coagulation in a case of Clostridium perfringens septicemia. BMJ 1967;3:271-279
34. Cronberg S, Skansberg P, Nivenios-Larsson K. Disseminated intravascular coagulation in septicemia caused by beta-hemolytic stretococci. Thromb Res 1973;3:405-414
35. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985;29:81-89
36. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemostas 1989;15:347-352
37. Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888
38. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces, comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995;85:121-129
39. Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation system in normal individuals and septic shock patients. Circ Shock 1982;9:491-497
40. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
41. Taylor FB, Chang ACK, Peer GT, et al. DEGR-FXa blocks disseminated intravascular coagulation initiated by E. coli without preventing shock or organ damage. Blood 1991;78:364-368
42. Schipper HG, Jenkins CSP, Kahl LH, ten Cate JW. Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1978;I:854-856
43. Hellgren M, Javelin L, Hägnevik K, Blombäck M, Meden-Britth G. Antithrombin III concentrate as adjuvant in DIC treatment - a pilot study in 9 severely ill patients. Thromb Res 1984;36:459-460
44. Vinazzer H. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thromb/Hemostas 1995;1: 62-65
45. Kirchmaier CM, Bender N, Oehm H, Breddin H. Therapeutic use of antithrombin in septicaemia in adults. Biol Clin Hematol 1987;9:113-119
46. Seitz R, Wolf M, Eghring R, Havemann K. The disturbance of haemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma. Eur J Haematol 1989;43:22-28
47. Balk R, Bedrosian C, McCormick L, Baugham J. Prospective double-blind, placebo-ontrolled trial of AT III substitution in sepsis. In: Roussos C, ed. 8th European Congress of Intensive Care Medicine. Bologna: Monduzzi Editore; 1995; 7-11
48. Guidici D, Gallioli G, Wolfler A, et al. AT III in the ICU patient: A randomized double blind trial. In: Braschi A, Chiaranda M, Gattinoni L, Pesenti A, Raimondi F, eds. Simposio mostra anestesia rianimazione e terapia intensiva. Berlin, Heidelberg: Springer; 1997; 9-12
49. Schuster HP, Matthias FR. 15th International Symposium on Intensive Care and Emergency Medicine. Brussels; March, 21-24, 1995
50. Lamy M, Eisele B, Keinecke HO, Delvos U, Thijs LG. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial. In: Bennett D, ed. 9th European Congress on Intensive Care Medicine. Bologna: Monduzzi Editore; 1996; 385-390